The modern C-suite is no longer judged by how many strategies it produces but by the outcomes it builds and the speed with ...
Thomas Yau and colleagues’ CheckMate 9DW trial has yielded unprecedented results, with nivolumab plus ipilimumab reaching an overall response rate of 36%, a median progression-free survival of 9·1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback